Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2024

Genmab — Oktober 2024

Planlagt Fastgjort Låst Flyttet Genmab
991 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #815

    Ja det er rigtigt gentogen, den kan potentielt blive mange penge værd også uden opt-in. Kommer straks til at tænke pæ om gmab kan rejse ny voldgift for EU nu da fastpro er domt til ikke at været patenterbart produkt?

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #816

      Ja den tanke smed jeg også ind i går. Men voldgiften er bindende og derfor nok svær at få genoptaget. Men interessant spørgsmål.

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #817

        JNJ er helt tavs omkring EU patententet eller manglende. Er der nogen der har set selve afgørelsen ?

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #818

          Jeg har ledt efter den uden held. Måske mesteren EL kan trylle den frem..., men jeg tror ikke nu ikke, at den er offentliggjort

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #819

            Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting https://www.prnewswire.com/news-releases/traverse-biotech-to-present-data-on-ror2-targeted-t-cell-engager-at-the-society-for-immunotherapy-of-cancers-sitc-39th-annual-meeting-302286375.html TB-Bs1 is a first-in-class T-cell Engaging (TCE) bispecific antibody built on the DuoBody™ platform targeting ROR2.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #820

              on HALO ; my understanding is that EPO will send a written form of the decision in a few weeks, JNJ then has ~2 months to appeal. During the appeal the EPO decision is suspended and the patent remains in force. Such an appeal can take ~2 years

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #821

                Maybe we can learn more if we see that EPO write up, I assume that will be public info

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #822

                  Third week in a row that the US volume was higher than the Copenhagen volume. I am not sure if we have seen that before

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #823

                    In my opinion it was US that took Genmab down. Would not be surpriced to se them take it up again. Well JNJ has take the uncertainty about their faspro in consideration when they decide the opt. on Erzo. Thanks EL for the link to Traverse Biotech - interesting target for Genmab.

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bikube
                      wrote on sidst redigeret af
                      #824

                      Kursen i U S plejer at være lidt højere end i DK både på GMAB og Novo.

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #825

                        Dollar er sgu da også højre end danske kroner !. Niveauet er ved at blive lidt for lavt herinde. God weekend 😉

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bikube
                          wrote on sidst redigeret af
                          #826

                          Lahn - tror du kke, at jeg omregner $ til DKK inden jeg skriver ? Hvis du vil give lidt ekstra, kan du jo købe GMAB i U S.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #827

                            Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma https://www.onclive.com/view/bispecific-antibodies-novel-combinations-highlight-continued-treatment-evolution-in-follicular-lymphoma

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              lahn1
                              wrote on sidst redigeret af
                              #828

                              Undskyld bikube, den var sagt for sjov. Fortsat god weekend.

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bikube
                                wrote on sidst redigeret af
                                #829

                                I orden Lahn.

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #830

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #831

                                    Genmab-investorerne får tirsdag morgen nyt fra Schweiz, hvor Novartis’ regnskab også byder på tal for der også byder på sklerosemidlet Kesimpta, der er udviklet af det danske biotekselskab. Genmab modtager royalties på 10 pct. af salget, der i andet kvartal blev på 799 mio. dollar.

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      bikube
                                      wrote on sidst redigeret af
                                      #832

                                      Er der nogen, der har set tallene fra Novartis ?

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bikube
                                        wrote on sidst redigeret af
                                        #833

                                        Undskyld - det er i morgen, de kommer.

                                        1 Reply Last reply
                                        0
                                        • exitnuE Offline
                                          exitnuE Offline
                                          exitnu
                                          wrote on sidst redigeret af
                                          #834

                                          Upcoming event: Oct 29, 2024 - Third quarter 2024 results

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper